Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amolimogene in High-Grade Cervical Intraepithelial Lesions
NCT00264732Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2005
- Primary completion
- May 2009
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
A Phase 3 trial of amolimogene bepiplasmid in cervical intraepithelial neoplasia (CIN), sponsored by Eisai Co., Ltd.. Started Jul 2005; status: completed.
02
Drugs
amolimogene bepiplasmid
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT00264732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00264732.